AVM Biotechnology is led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and four discoveries in clinical trials. The Executive Board is comprised of leaders in the areas of respiratory illness, regulatory affairs, and vaccine development, and AVM is guided by a global Advisory Board including well-respected leaders in cancer and immunology. AVM holds eight worldwide patent families that cover the use and formulation of its lead drug, AVM0703, and has been awarded two SBIR grants.